Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Februar 2022 07:30 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics

PURCHASE, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases,...
10. Januar 2022 07:30 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
04. Januar 2022 07:30 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases,...
21. Dezember 2021 07:30 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics to Participate in Next-Generation Alzheimer’s Disease Panel at Virtual Biotech Showcase on January 11, 2022

PURCHASE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
30. November 2021 07:30 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation

PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
18. November 2021 08:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights

PURCHASE, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
15. November 2021 07:30 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering

PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
03. November 2021 08:00 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
08. Oktober 2021 07:30 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

PURCHASE, N.Y., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule...
04. Oktober 2021 07:54 ET | Quelle: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Launch of its Initial Public Offering

PURCHASE, N.Y., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule...

Vorherige Seite